{"id":7515,"date":"2025-06-25T17:26:45","date_gmt":"2025-06-25T14:26:45","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7515"},"modified":"2025-06-25T17:26:45","modified_gmt":"2025-06-25T14:26:45","slug":"eligibility-criteria-for-renal-denervation","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/eligibility-criteria-for-renal-denervation\/","title":{"rendered":"Eligibility Criteria for Renal Denervation"},"content":{"rendered":"<div>Eligibility Criteria for Renal Denervation<\/div>\n<div>Source: Secemsky EA, et al. JACC: Cardiovascular Interventions, June 4, 2025<\/div>\n<div><\/div>\n<div>1. FDA-Approved Device Criteria<\/div>\n<div><\/div>\n<div>Used to identify eligible patients for the two recently approved RDN systems:<\/div>\n<div><span> \u2022 Adults (\u226518 years old)<\/span><\/div>\n<div><span> \u2022 Diagnosed with uncontrolled hypertension<\/span><\/div>\n<div><span> \u2022 Taking three or more antihypertensive medications, including a diuretic<\/span><\/div>\n<div><span> \u2022 Blood pressure remains elevated despite adherence to therapy<\/span><\/div>\n<div><span> \u2022 No significant renal artery stenosis or secondary causes of hypertension<\/span><\/div>\n<div><\/div>\n<div>\u2192 Estimated eligible population: Up to 35 million U.S. adults<\/div>\n<div><\/div>\n<div>2. Randomized Sham-Controlled Trial Criteria<\/div>\n<div><\/div>\n<div>These criteria are highly selective and reflect the inclusion used in pivotal RDN trials:<\/div>\n<div><span> \u2022 On stable antihypertensive regimen<\/span><\/div>\n<div><span> \u2022 Office systolic BP \u2265140 mmHg despite treatment<\/span><\/div>\n<div><span> \u2022 Adherence strictly confirmed<\/span><\/div>\n<div><span> \u2022 Exclusion of complex comorbidities or severe CKD<\/span><\/div>\n<div><\/div>\n<div>\u2192 Estimated eligible population: Only ~2% of hypertensive U.S. adults<\/div>\n<div><\/div>\n<div>3. SCAI 2023 Clinical Consensus Statement Criteria<\/div>\n<div><\/div>\n<div>Broader, more inclusive, and designed for real-world application:<\/div>\n<div><span> \u2022 Patients with resistant or uncontrolled hypertension<\/span><\/div>\n<div><span> \u2022 Includes those intolerant to medications<\/span><\/div>\n<div><span> \u2022 Focus on a comprehensive clinical assessment beyond BP numbers alone<\/span><\/div>\n<div><span> \u2022 Recommends shared decision-making and individualized consideration<\/span><\/div>\n<div><\/div>\n<div>\u2192 Estimated eligible population: ~25 million U.S. adults<\/div>\n<div><\/div>\n<div>Key Insight from the Study<\/div>\n<div><span> \u2022 While many patients meet eligibility, up to 30% of them may not benefit from RDN<\/span><\/div>\n<div><span> \u2022 No currently available tool reliably predicts RDN responders<\/span><\/div>\n<div><span> \u2022 Overuse may result in significant economic burden without outcome benefit<\/span><\/div>\n<div><a href=\"https:\/\/www.jacc.org\/doi\/full\/10.1016\/j.jcin.2025.05.007\">https:\/\/www.jacc.org\/doi\/full\/10.1016\/j.jcin.2025.05.007<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Eligibility Criteria for Renal Denervation Source: Secemsky EA, et al. JACC: Cardiovascular Interventions, June 4, 2025 1. FDA-Approved Device Criteria Used to identify eligible patients for the two recently approved RDN systems: \u2022 Adults (\u226518 years old) \u2022 Diagnosed with uncontrolled hypertension \u2022 Taking three or more antihypertensive medications, including a diuretic \u2022 Blood pressure [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7515","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7515"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7515\/revisions"}],"predecessor-version":[{"id":7523,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7515\/revisions\/7523"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7515"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}